Research Article
Management and Outcomes of ANCA-Associated Vasculitis at a Tertiary Healthcare Facility
Table 5
Summary of progression to ESRD/death, CKD, and preservation of renal function: induction and maintenance treatment.
| | Outcome | Induction: cyclophosphamide (n = 24) | Induction: rituximab (n = 7) | Induction: cyclophosphamide and rituximab (n = 1) | Induction: azathioprine (n = 22) | Maintenance: rituximab (n = 6) | Maintenance: azathioprine (n = 4) | Maintenance: corticosteroids alone (n = 6) | Maintenance: MMF (n = 1) | Maintenance: no treatment (n = 1) |
| | ESRD or death, % (n) | 41.7 (10) | 28.6 (2) | 0 (0) | 75 (3) | 6.7 (1) | 40.9 (9) | 66.7 (4) | 100 (1) | 0 (0) | | CKD, % (n) | 45.8 (11) | 28.6 (2) | 100 (1) | 25 (1) | 33.3 (2) | 50 (11) | 33.3 (2) | 0 (0) | 0 (0) | | Preservation of renal function, % (n) | 12.5 (3) | 42.9 (3) | 0 (0) | 0 (0) | 50 (3) | 9.1 (2) | 0 (0) | 0 (0) | 100 (1) |
|
|
